# PDL BIOPHARMA INC (Y104L)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/Y104L/

- Reporting holders: 6
- Reported value: $29.2K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [DIVERSIFIED TRUST CO](https://holderbook.com/funds/1479844-diversified-trust-co/) | $27.7K | 11,554 | 0.0% | 14 |
| [RHUMBLINE ADVISERS](https://holderbook.com/funds/1115418-rhumbline-advisers/) | $1.5K | 612 | 0.0% | 13 |
| [Financial Gravity Companies, Inc.](https://holderbook.com/funds/1377167-financial-gravity-companies-inc/) | $0 | 13 | 0.0% | 2 |
| [Westside Investment Management, Inc.](https://holderbook.com/funds/1538383-westside-investment-management-inc/) | $0 | 500 | 0.0% | 1 |
| [Argent Trust Co](https://holderbook.com/funds/1625292-argent-trust-co/) | $0 | 41,405 | 0.0% | 1 |
| [WELLINGTON-ALTUS USA INC.](https://holderbook.com/funds/1760398-wellington-altus-usa-inc/) | $0 | 275 | 0.0% | 3 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 6 | $29.2K |
| Q1 2026 | 3 | $29.2K |
| Q4 2025 | 3 | $28.0K |
| Q3 2025 | 2 | $28.0K |
| Q2 2025 | 3 | $28.0K |
| Q1 2025 | 2 | $28.0K |
| Q4 2024 | 2 | $28.0K |
| Q3 2024 | 2 | $28.0K |
| Q2 2024 | 2 | $28.0K |
| Q1 2024 | 2 | $28.0K |
| Q4 2023 | 3 | $130.2K |
| Q3 2023 | 3 | $130.2K |